|
Match
|
Document |
Document Title |
|
|
7348136 |
Method and device for detecting feline immunodeficiency virus
A method and device for determining a feline immunodeficiency virus infection or vaccination in an animal. The method includes contacting a biological sample from a felid with various FIV...
|
|
|
7306804 |
HIV-specific T-cell induction
This invention discloses diagnostic, preventative, and treatment therapies of AIDS involving determining whether a subject exhibits an HLA-Cw7-restricted CTL response. Some methods are directed to...
|
|
|
7118888 |
Gene expression vaccine
An effective prophylactic mucosal gene expression vaccine (GXV), made up of a cocktail of at least 4 different plasmid DNAs encoding corresponding RSV antigens, coacervated with chitosan to...
|
|
|
7118874 |
Immunogenic formulation and process for preparation thereof
A process is disclosed for preparation of a immunogenic peptide mixture in a single synthesis. The peptide mixture collectively represents the in vivo variability seen in immunogenic epitopes from...
|
|
|
7094550 |
Method to determine TGF-beta
A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I):
wherein Z is C═O or a covalent bond; Y is H or O(C 1 –C 4 )alkyl, R 1 and R 2...
|
|
|
7078483 |
Retroviral vectors including modified envelope escort proteins
A retroviral vector comprising a first retroviral envelope protein and at least one modified retroviral envelope protein, wherein the first retroviral envelope protein includes a surface protein...
|
|
|
7033751 |
Antigenic fragment of human T-lymphotropic virus
Antigenic fragments of human T-lymphotropic virus (HTLV), their fusion proteins with glutathione S-tranferase (GST) or thioredoxin (Thio), and a process for producing the fusion proteins thereof....
|
|
|
7022325 |
CD8 epitope from HIV-1 protein Vpu
The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an HIV infection. More particularly, the invention is concerned with peptides and...
|
|
|
6936246 |
Passive immunization of ASCR for prion disorders
Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the...
|
|
|
6806055 |
HIV envelopolype peptides
A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic...
|
|
|
6670466 |
Human endogenous retrovirus in breast cancer
The present invention is related to mammary tumor virus (MTV). MTV represents a group of retroviruses which possess very high homology to mouse mammary tumor virus (MMTV), a virus known to cause...
|
|
|
6602705 |
Expression of HIV polypeptides and production of virus-like particles
The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression...
|
|
|
6602505 |
Viral chimeras comprised of CAEV and HIV-1 genetic elements
The invention provides a polynucleotide comprising portions of the genomes of caprine arthritis-encephalitis virus and HIV-1, resulting in a chimeric retrovirus referred to as a “CHIV. ” The...
|
|
|
6582703 |
Isolated nucleotide sequences associated with multiple sclerosis or rheumatoid arthritis and a process of detecting
The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in methods of diagnosis, prophylaxis, and therapy.
|
|
|
6579526 |
Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
Viral material, in the isolated or purified state, in which the genome comprises a nucleotide sequence chosen from the group including sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID...
|
|
|
6573091 |
Chimeric viral packaging signal without gag gene sequences
A chimeric viral packaging signal is described for the transmission of genetic materials via retrovirus. The packaging signal contains an essential packaging nucleic acid sequence and a...
|
|
|
6528250 |
Equine infectious anemia challenge model for testing vaccines, diagnostics and treatments
The invention relates to a method for infecting equines with an equine infectious anemia virus (EIAV) in order to reproduce a natural infection challenge model. More specifically, the invention...
|
|
|
6514692 |
Method for treatment of immunodeficiency virus infection
The present invention relates to methods for treating immunodeficiency virus infection in an infected animal comprising administering an effective amount of a lytic peptide.
|
|
|
6495315 |
Channel forming toxins as antiviral agents
The infectivity of a population of enveloped viruses which comprise a glycosylphosphatidylinositol-anchored protein in their membrane can be reduced by employing certain toxins such as aerolysin,...
|
|
|
6455265 |
Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral infection
A method of searching for and obtaining a vaccine against the pathogenic effects related to the infection of an animal or human host by a retrovirus that penetrates into a target cell of the host,...
|
|
|
6444442 |
Method of producing a recombinant non-glycosylated gp90 of equine infectious anemia virus (EIAV), and product thereof
The present invention describes recombinant gp90 envelop protein derived from the equine infectious anemia virus, their corresponding encoding recombinant DNA molecule and the process of production...
|
|
|
6406841 |
Methods for the detection of HTLV-II antibodies employing novel HTLV-II NRA envelope peptides
The present invention relates generally to a novel human T-cell lymphotropic, or leukemia, virus type II (HTLV-II) isolate designated NRA. HTLV-II NRA was originally isolated from a patient with...
|
|
|
6392029 |
HIV chemokines
Disclosed is a gene comprising an open reading frame encoded on the plus strand of the pro-viral DNA, and located in the region of HIV-1 long terminal repeat. The gene encodes a protein that is...
|
|
|
6365727 |
DNA and peptides of a diabetes-specific endogenous retrovirus
The present invention relates to gene and peptide sequences of a diabetes-specific endogenous retrovirus which is derived from type 1 diabetes patients. In particular, the present invention relates...
|
|
|
6326007 |
Attenuated lentivirus vectors expressing interferon
This invention discloses recombinant vectors and live attenuated pathogens produced by these vectors which are useful as vaccines and therapeutic agents. Particularly disclosed are live attenuated...
|
|
|
6287572 |
Anti-HIV peptides and proteins
This invention relates to novel peptides and proteins and nucleic acids encoding them, which are useful against HIV infection. The peptides comprise an amino acid sequence of a part of the HIV-1...
|
|
|
6287565 |
Modified HGP-30 heteroconjugates, compositions and methods of use
A heteroconjugate is formed by linking a T cell binding ligand (TCBL) such as Peptide J of β-2 microglobulin to a modified HGP-30 antigentic peptide fragment of p17 gag peptide, such as, for...
|
|
|
6261806 |
Molecular sequence of swine retrovirus and methods of use
This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such...
|
|
|
6184025 |
Viral isolates associated with multiple sclerosis
Composition comprising two pathogenic and/or infective agents associated with multiple sclerosis, namely a first agent which consists of a human virus possessing reverse transcriptase activity and...
|
|
|
6146628 |
Biotherapeutic agents comprising recombinant PAP and PAP mutants
Biotherapeutic agents are provided which comprise recombinant PAP or a biologically equivalent variant or mutant thereof, linked to a targeting moiety which are effective for the treatment of...
|
|
|
6143330 |
Compositions for inhibiting dental caries and/or middle ear infections and uses thereof
Compositions for treating or preventing dental caries and/or middle ear infections. These compositions comprise antibodies to dental caries and/or antibodies to bacteria causing middles ear...
|
|
|
6140114 |
Defective viral vaccine particles obtained in vivo or ex vivo
The present invention relates to a vaccine consisting of defective viral particles as are obtained in vivo or ex vivo, in individuals infected or capable of being infected with a virus, after...
|
|
|
6136319 |
Method of treating viral diseases in animals
A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a...
|
|
|
6132731 |
Murine leukemia virus vectors
A proteinaceous particle comprises a capsid enveloped by ecotropic Murine Leukemia virus envelope proteins characterized in that a heterologous peptide which binds to a non-murine cell is inserted...
|
|
|
6129921 |
Viral ribonucleocapsid as an immunological enhancer
Methods of enhancing an antigen-induced immune response through use of a ribonucleocapsid complex are provided. Composition containing a ribonucleocapsid complex and an antigen which are capable of...
|
|
|
6113902 |
Immunogenic compositions comprising peptides from β-2-microglobulin
An immunogenic composition for treating and/or preventing infectious diseases where the infectious agent has at least one intracellular phase in the host during its multiplication cycle, is...
|
|
|
6033672 |
Method of stimulating an immune response to caprine arthritis-encephalitis virus (CAEV) in humans through the administration of CAEV immunogens
The present invention provides a vaccine comprising a caprine arthritis-encephalitis virus (CAEV) immunogen and a pharmaceutically acceptable carrier. The invention also provides a method of...
|
|
|
6025141 |
Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form
|
|
|
6013506 |
Feline leukemia virus vaccines
Disclosed are recombinant baculovirus expressing the gag, gp70, and gp85 genes of feline leukemia virus. Also disclosed are vaccines based on protein expressed from these recombinants. Also...
|
|
|
5962446 |
Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
A method for treating human T cell lymphotrophic virus type 1 infection using an isozyme selective PKC inhibitor, particularly using the isozyme selective PKC inhibitor, (S)-3,4-...
|
|
|
5962217 |
MSRV1 virus and MSRV2 pathogen and/or infective agent associated with multiple sclerosis, and biopolymer constituents thereof
Composition including two pathogenic and/or infective agents associated with multiple sclerosis, namely a first agent which consists of a human virus possessing reverse transcriptase activity and...
|
|
|
5919462 |
Nucleic acid fragments derived from the HIV-1 virus genome, corresponding peptides and their applications as reagents for evaluation of the risk of maternofoetal transmission of HIV-1
This invention provides specific amino acid sequences encoded by nucleic acid fragments derived from the genome of the human immunodeficiency virus type 1 (HIV-1) and to peptides containing such...
|
|
|
5871996 |
Retrovirus agents MSRV1 and MSRV2 associated with multiple sclerosis
Composition including two pathogenic and/or infective agents associated with multiple sclerosis, namely a first agent which consists of a human virus possessing reverse transcriptase activity and...
|
|
|
5871745 |
Multiple sclerosis related virus
Composition including two pathogenic and/or infective agents associated with multiple sclerosis, namely a first agent which consists of a human virus possessing reverse transcriptase activity and...
|
|
|
5866137 |
Self-assembled, non-infectious, non-replicating; immunogenic retrovirus-like particles comprising modified HIV genomes devoid of long terminal repeats and chimeric envelope glycoproteins
This invention is directed toward self-assembled, non-infectious, non-replicating, immunogenic retrovirus-like particles comprising modified HIV-1 genomes devoid of long terminal repeats and...
|
|
|
5853738 |
Methods for treatment of human immunodeficiency virus infection with pseudomonas phosphoaminolipid extract
The present invention is directed to a method of treating individuals infected with HIV or at risk of being infected with HIV. The method comprises the step of administering to an individual...
|
|
|
5849475 |
Immunoassay diagnostic kit containing antigens derived from self-assembled, non-infectious, non-replicating, immunogenic retrovirus-like particles comprising modified HIV genomes and chimeric envelope glycoproteins
This invention is directed toward diagnostic kits and antigens useful for the detection of viral antigens in a test sample. The kit contains antigens obtained from self-assembled, non-infectious,...
|
|
|
5837818 |
Construction and expression of synthetic genes encoding envelope epitopes of the human T cell leukemia virus type I
A synthetic gene which codes for at least one epitope from the immunodominant conserved region of HTLV-I env. gp 21 as well as hybrid genes utilizing the synthetic gene in conjunction with other...
|
|
|
5736378 |
Molecular cloning and characterization of the feline immunodeficiency virus isolate PPR
Molecular clones of the feline immunodeficiency virus isolate PPR (FIV PPR ) were obtained from a genomic library prepared from infected feline peripheral blood lymphocytes (PBLs). FIV PPR ...
|
|
|
5718901 |
Feline calicivirus gene
The present invention provides recombinant DNA molecules comprising a sequence encoding a feline calicivirus polypeptide, particularly the capsid protein, host cells transformed by recombinant DNA...
|